{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:57:35Z","timestamp":1794643055813,"version":"4.9.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Janus kinase 2 mutation, JAK2617V&gt;F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes. Furthermore, JAK2617V&gt;F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV), whereas JAK2617V&gt;F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Therefore, JAK2 mutation screening holds the promise of a decisive diagnostic test in PV while being complementary to histology for the diagnosis of ET and PMF; the combination of molecular testing and histologic review should also facilitate diagnosis of ET associated with borderline thrombocytosis. Accordingly, revision of the current World Health Organization (WHO) diagnostic criteria for PV, ET, and PMF is warranted; JAK2 mutation analysis should be listed as a major criterion for PV diagnosis, and the platelet count threshold for ET diagnosis can be lowered from 600 to 450 \u00d7 109\/L. The current document was prepared by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders; it was subsequently presented to members of the Clinical Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms, who endorsed the document and recommended its adoption by the WHO.<\/jats:p>","DOI":"10.1182\/blood-2007-04-083501","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T22:43:16Z","timestamp":1178664196000},"page":"1092-1097","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":681,"title":["Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel"],"prefix":"10.1182","volume":"110","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Thiele","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Michael","family":"Kvasnicka","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico, San Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Birgegard","sequence":"additional","affiliation":[{"name":"University Hospital, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Reilly","sequence":"additional","affiliation":[{"name":"Royal Hallamshire Hospital, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[{"name":"Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"University of Illinois, Chicago;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gary","family":"Gilliland","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara D.","family":"Bloomfield","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Vardiman","sequence":"additional","affiliation":[{"name":"University of Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111714091203000_B1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders.","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle"},{"key":"2019111714091203000_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111714091203000_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111714091203000_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111714091203000_B5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111714091203000_B6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes.","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"2019111714091203000_B7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"2019111714091203000_B8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111714091203000_B9","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"2019111714091203000_B10","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"2019111714091203000_B11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111714091203000_B12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2141.2005.05517.x","article-title":"An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.","volume":"129","author":"Johansson","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111714091203000_B13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera.","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111714091203000_B14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.beha.2005.07.006","article-title":"Idiopathic erythrocytosis and other non-clonal polycythemias.","volume":"19","author":"Finazzi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111714091203000_B15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.leu.2404069","article-title":"Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.","volume":"20","author":"James","year":"2006","journal-title":"Leukemia"},{"key":"2019111714091203000_B16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"2019111714091203000_B17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/10428190500331329","article-title":"A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.","volume":"47","author":"Thiele","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2019111714091203000_B18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4065\/80.7.923","article-title":"How to interpret and pursue an abnormal complete blood cell count in adults.","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2019111714091203000_B19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.7326\/0003-4819-139-6-200309160-00009","article-title":"The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.","volume":"139","author":"Ruggeri","year":"2003","journal-title":"Ann Intern Med"},{"key":"2019111714091203000_B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2141.1998.00529.x","article-title":"Should a platelet limit of 600 x 10(9)\/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.","volume":"100","author":"Lengfelder","year":"1998","journal-title":"Br J Haematol"},{"key":"2019111714091203000_B21","first-page":"492","article-title":"Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)\/L: Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).","volume":"85","author":"Sacchi","year":"2000","journal-title":"Haematologica"},{"key":"2019111714091203000_B22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4065\/80.7.947","article-title":"The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2019111714091203000_B23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-2006-939433","article-title":"Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.","volume":"32","author":"Thiele","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2019111714091203000_B24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2006.01.004","article-title":"Mutation screening for JAK2V617F: when to order the test and how to interpret the results.","volume":"30","author":"Tefferi","year":"2006","journal-title":"Leuk Res"},{"key":"2019111714091203000_B25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/10428199909058421","article-title":"Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.","volume":"33","author":"Thiele","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"2019111714091203000_B26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2005.04.010","article-title":"Hematopathologic findings in chronic idiopathic myelofibrosis.","volume":"32","author":"Thiele","year":"2005","journal-title":"Semin Oncol"},{"key":"2019111714091203000_B27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0889-8588(03)00086-8","article-title":"The myelodysplastic\/myeloproliferative disorders: the interface.","volume":"17","author":"Bennett","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111714091203000_B28","first-page":"381","article-title":"Cytogenetic findings in untreated patients with essential thrombocythemia.","volume":"20","author":"Panani","year":"2006","journal-title":"In Vivo"},{"key":"2019111714091203000_B29","unstructured":"Mitelman F Johansson B Mertens F Mitelman database of chromosome aberrations in cancer, 2007. Accessed March 14, 2007 http:\/\/cgap.nci.nih.gov\/Chromosomes\/Mitelman."},{"key":"2019111714091203000_B30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000064754","article-title":"Cytogenetic and molecular genetic aspects of essential thrombocythemia.","volume":"108","author":"Steensma","year":"2002","journal-title":"Acta Haematol"},{"key":"2019111714091203000_B31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"31","author":"Mesa","year":"2007","journal-title":"Leukemia Res"},{"key":"2019111714091203000_B32","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019111714091203000_B33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/modpathol.3800348","article-title":"Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia.","volume":"18","author":"Orazi","year":"2005","journal-title":"Mod Pathol"},{"key":"2019111714091203000_B34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1991.tb04411.x","article-title":"Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity.","volume":"78","author":"Lambertenghi-Deliliers","year":"1991","journal-title":"Br J Haematol"},{"key":"2019111714091203000_B35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.beha.2005.07.015","article-title":"Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.","volume":"19","author":"Thiele","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111714091203000_B36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0145-2126(01)00055-8","article-title":"Myelodysplasia with fibrosis: a distinct entity?","volume":"25","author":"Steensma","year":"2001","journal-title":"Leuk Res"},{"key":"2019111714091203000_B37","first-page":"392","article-title":"Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.","volume":"87","author":"Schmitt-Graeff","year":"2002","journal-title":"Haematologica"},{"key":"2019111714091203000_B38","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.leu.2404405","article-title":"High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","volume":"20","author":"Renneville","year":"2006","journal-title":"Leukemia"},{"key":"2019111714091203000_B39","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.leu.2404316","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.","volume":"20","author":"Wang","year":"2006","journal-title":"Leukemia"},{"key":"2019111714091203000_B40","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2006-02-005751","article-title":"Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.","volume":"108","author":"Szpurka","year":"2006","journal-title":"Blood"},{"key":"2019111714091203000_B41","first-page":"719","article-title":"Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic\/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.","volume":"91","author":"Remacha","year":"2006","journal-title":"Haematologica"},{"key":"2019111714091203000_B42","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.leu.2404373","article-title":"The JAK2 V617F mutation is rare in RARS but common in RARS-T.","volume":"20","author":"Ceesay","year":"2006","journal-title":"Leukemia"},{"key":"2019111714091203000_B43","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2006-05-022491","article-title":"High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109\/L) and ringed sideroblasts more than 15% considered as MDS\/MPD, unclassifiable.","volume":"109","author":"Gattermann","year":"2007","journal-title":"Blood"},{"key":"2019111714091203000_B44","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"2019111714091203000_B45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00277-002-0604-y","article-title":"Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.","volume":"82","author":"Thiele","year":"2003","journal-title":"Ann Hematol"},{"key":"2019111714091203000_B46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-2006-942757","article-title":"The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.","volume":"32","author":"Kvasnicka","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2019111714091203000_B47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00277-004-0881-8","article-title":"Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up.","volume":"83","author":"Thiele","year":"2004","journal-title":"Ann Hematol"},{"key":"2019111714091203000_B48","first-page":"1026","article-title":"Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.","volume":"5","author":"Soligo","year":"1991","journal-title":"Leukemia"},{"key":"2019111714091203000_B49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.2005.05593.x","article-title":"Der(6)t(1;6)(q21\u201323; p213): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.","volume":"130","author":"Dingli","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111714091203000_B50","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111714091203000_B51","first-page":"633","article-title":"Standardization of bone marrow features\u2013does it work in hematopathology for histological discrimination of different disease patterns?","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol Histopathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1092\/1478525\/zh801607001092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1092\/1478525\/zh801607001092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T16:19:30Z","timestamp":1587485970000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/4\/1092\/23098\/Proposals-and-rationale-for-revision-of-the-World"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-04-083501","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1087119.540101","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}